Get Our Free Research Email
Conference Calendar 
May 17-19 - 2012 AANA Annual Meeting
May 20-23 - Current Concepts in Joint Replacement Spring 2012
Complete Calendar »
|
Orthopedic and Dental Industry News
September 2003
Orthopedics, the self-made industry, is troubled and struggling. At least that was the tone at last week's OrthoKnow Symposium (one of the best of such industry gatherings) as distributors and their fellow travelers gathered to discuss the state of orthopedics.... more
But the conference call explaining the decision isn't scheduled until October 3rd. So why announce now? Word was leaking out and instead of letting rumors erode employee morale, management decided to get in front of the news. That makes sense.... more
Dave Stassen, legendary medical device venture capitalist and principal at the $3 billion St. Paul Ventures in Minnesota is calling a turn in medical device venture investment. In his talk at the OrthoKnow symposium last week, Stassen recounted the recent... more
The data we see coming from the Centers for Medicare and Medicaid (CMS) tells us that the large joint reconstruction market is being driven by people born before 1944. Not Boomers. Not Zoomers – whatever they are – or any... more
Presenting at our October 9th Spine Summit will be, in no particular order: The most innovative supplier of hemostatic products for the spine that no one has heard of. The best surgical assist (a semi-robot) for spine surgeons we've ever... more
What makes the Orthopedic Industry's current renaissance so interesting is not only how unexpected it is, but how unexpectedly broad and deep it is. Unlike the cardiovascular industry, which is riding the drug coated stent phenomenon, orthopedic revenues are bubbling... more
86.7% of the outstanding shares of Centerpulse held by individual shareholders or Incentive Capital have been tendered to Zimmer. Ray Elliott, CEO of Zimmer Holdings, is now an ex-officio member of the American Swiss Foundation Board of Directors. (The Foundation... more
GenSci Orthobiologics is in the final stages of emerging from Chapter 11 bankruptcy. ISOTIS, the Netherlands based tissue engineering company, is merging with GenSci and setting the stage for a dramatic and interesting rebirth of this company that many, including... more
In this era of recombinant bone morphogenic proteins that cost $5,000 per patient per level, it's refreshing to note that there are more ways to jump start bone healing. Last week, Orthofix announced it had submitted data to the FDA... more
Here's a trick question for all you orthopods reading this newsletter. Name the bone void fill for spinal applications with 9 years of documented clinical success, an FDA controlled randomized clinical trial and over 75,000 cases at 1,500 hospitals. Grafton?... more
We told you so. We said orthopedic industry revenues were accelerating. We just didn't predict that they'd be this strong. We were thinking 16%. Now that the last conference call of the second quarter is over, we've added up all... more
Complete Archive
|
